External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Dr. Reddy's Laboratories / Equity Bottom-Up

<ul>
<li>Dr Reddy’s (DRRD) is going to acquire Haleon’s global portfolio of consumer healthcare brands (Northstar Switzerland) in the Nicotine Replacement Therapy (NRT) category outside of the US</li>
<li>The proposed acquisition will be inclusive of all formats such as lozenge, patch, and gum as well as pipeline products</li>
<li>The total consideration of GBP 500 mn (upfront cash of GBP 458 mn and performance-based contingent payments of ~GBP 42 mn) implies 2.3x EV/sales for CY23 (reported sales of GBP 217 mn in CY23 and ~4% CAGR over CY21-23)</li>
</ul>
<p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>


Dr Reddy’s (DRRD) is going to acquire Haleon’s global portfolio of consumer healthcare brands (Northstar Switzerland) in the Nicotine Replacement Therapy (NRT) category outside of the US
The proposed acquisition will be inclusive of all formats such as lozenge, patch, and gum as well as pipeline products
The total consideration of GBP 500 mn (upfront cash of GBP 458 mn and performance-based contingent payments of ~GBP 42 mn) implies 2.3x EV/sales for CY23 (reported sales of GBP 217 mn in CY23 and ~4% CAGR over CY21-23)

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dr Reddy’s Laboratories: To Acquire Global OTC Portfolio for Ex-US Market.